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Abstract IgG4-related dacryoadenitis and sialoadenitis (IgG4-DS) is characterized by bilateral
swelling of glandular tissues with extensive fibrosis, and is immunologically considered a
Th2-predominant disease. Recent studies reported that alternatively activated (M2) macrophages
enhanced Th2 immune responses and fibrosis by production of pro-fibrotic factors (IL-10, IL-13 and
CCL18). Therefore, we examined the association between M2 macrophages and fibrosis in sub-
mandibular glands from 7 patients with IgG4-DS, 10 patients with chronic sialoadenitis, 10 patients
with Sjögren's syndrome, and 10 healthy subjects. The number of M2 macrophages in SMGs from
patients with IgG4-DS was also significantly higher than in the other groups. Double immunofluores-
cence staining showed that IL-10 and CCL18 expression co-localized with M2 macrophage-marker
(CD163). Furthermore, the SMG fibrosis score was positively correlated with the frequency of M2
macrophages in only IgG4-DS. These results indicate that IL-10 and CCL18 secreted by preferential M2
macrophages possibly play a key role in the development of severe fibrosis in IgG4-DS.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the
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10 S. Furukawa et al.1. Introduction
Mikulicz's disease (MD), first reported by Mikulicz in 1888 [1],
is characterized by firm swelling of submandibular glands
(SMGs) and lacrimal glands (LGs), and has been considered to
be a subtype of Sjögren's syndrome (SS) because of these
histopathological similarities [2]. However, Yamamoto et al.
reported that patients diagnosed with MD also had high
serum levels of IgG4 and marked infiltration of IgG4-positive
plasma cells in salivary glands [3]. Moreover, several reports
also demonstrated that these findings were accompanied by
autoimmune pancreatitis (AIP) [4], sclerosing cholangitis (SC)
[5], tubulointerstitial nephritis (TIN) [6], interstitial pneumo-
nia [7], Hashimoto's thyroiditis [8] and Küttner tumor [9].
These diseases are now collectively called “IgG4-related
disease (IgG4-RD)” and we have described this concept and
provided up-to-date information regarding this emerging
disease entity in a recent review [10]. Furthermore, recent
studies have also referred to MD as IgG4-related dacryoadenitis
and sialoadenitis (IgG4-DS) [11].
Regarding the immunological aspect of IgG4-RD, it is well
known that IgG4 is induced by T helper type 2 cell (Th2)
cytokines such as interleukin (IL)-4 and IL-13. We previously
reported that analysis of peripheral CD4+ Th cells from
patients with IgG4-DS revealed a deviation in the Th1/Th2
balance favoring Th2 [12] and that Th2 cells play a key role in
the production of IgG4 and formation of ectopic germinal
centers (eGCs) [13,14]. In addition, Watanabe et al. reported
that abnormal immune responses might enhance the Th2
response via Toll-like receptors expressed by macrophages,
contributing to the immunopathology of IgG4-RD [15]. Recent
studies reported that rituximab targeting CD20 plasma cells
appeared to be an effective treatment strategy for IgG4-RD,
but plasmablasts lack surface expression of CD20 and thus
demonstrate a resistance to direct depletion by rituximab and
IgG4-positive plasmablast. Macrophage might play an effec-
tive role in IgG4 production produced by IgG4-positive
plasmablast. Recently, innate immune system such as macro-
phages has received a lot of attention to the initiation of
IgG4-RD [16]. At least two distinct subtypes of macrophages
have been identified; the classically activated (M1) macro-
phage stimulated by Th1 responses and the alternatively
activated (M2) macrophage stimulated by Th2 responses. M2
macrophages contribute to angiogenesis, suppression of
adaptive immunity, and wound healing and fibrosis [17,18].
Histologically, the critical features of IgG4-RD are severe
fibrosis with dense lymphoplasmacytic infiltration of the
salivary glands and other lesion [19]. However, to our
knowledge, no published reports have investigated the
mechanism promoting severe fibrosis in IgG4-RD. In this
study, we examined the distribution of macrophage subsets
and the expression of pro-fibrotic factors in salivary glands to
clarify the contribution of macrophages to the pathogenesis of
IgG4-DS.
2. Material and methods
2.1. Patients
SMG samples were collected from 7 patients with IgG4-DS
(five men and two women; mean age ± standard deviation
Table 2 Comparison of clinical and serological findings
between primary Sjögren's syndrome and IgG4-DS.
SS (n = 10) IgG4-DS
(n = 7)
Mean age (years) 61.5 ± 14.9 61.7 ± 12.1
Men:women 5:5 5:2
Frequency of elevated
serum IgG
60.0% (6/10) 71.4% (5/7)
bMean ± SD (mg/dL)N b2135.3 ±
757.0N
b2732.3 ±
2037.4N
Frequency of elevated
serum IgG4
ND 100.0% (7/7)
bMean ± SD (mg/dL)N bNDN b545.0 ± 448.6N
Frequency of
elevated ANA
100.0% (10/10) 42.9% (3/7)
Anti-SS-A/Ro 100.0% (10/10) 0.0% (0/7)
Anti-SS-B/La 40.0% (4/10) 0.0% (0/7)
Frequency of other
organs diagnosed
with IgG4-RD
None Pancreas:
57.1% (4/7)
Kidney:
14.3% (1/7)
Lung:
14.3% (1/7)
Prostate:
14.3% (1/7)
Abbreviations: SS, Sjögren's syndrome; IgG4-RD,
IgG4-related disease. Data are presented as the mean ± SD.
11M2 macrophages in IgG4-related dacryoadenitis and sialoadenitis(SD), 61.7 ± 12.1 years), 10 patients with chronic sialoadenitis
(CS) caused by sialolith (five men and five women; 51.5 ±
17.2 years), 10 patients with SS (five men and five women;
61.5 ± 14.9 years), and 10 patients with oral squamous cell
carcinoma (OSCC) as a control group (five men and five
women; 58.4 ± 16.3 years) who were referred to the Depart-
ment of Oral and Maxillofacial Surgery, Kyushu University
Hospital between 2010 and 2013. Patients underwent the
following procedures: (1) open SMG biopsies for IgG4-DS
and SS patients as described by Moriyama et al. [20]; (2)
submandibulectomy for CS patients; and (3) neck dissec-
tion for OSCC patients. SMGs from OSCC patients were
histologically normal and had no clinical evidence of metas-
tasis. IgG4-DS was diagnosed according to both the “Compre-
hensive diagnostic criteria for IgG4-related disease” [10] and
“Diagnostic criteria for IgG4-related Mikulicz's disease” [21].
The clinical and serological characteristics of the 7 patients
with IgG4-DS are summarized in Table 1. SS was diagnosed
according to both the Research Committee on SS of the
Ministry of Health and Welfare of the Japanese Government
(1999) [22] and the American–European Consensus Group
criteria for SS [23]. Each patient showed objective evidence of
salivary gland involvement based on the presence of subjec-
tive xerostomia and a decreased salivary flow rate, abnormal
findings on parotid sialography and focal lymphocytic infil-
trates in the labial salivary glands. There was no documented
history of treatment with steroids, infection with HIV, HTLV-1,
hepatitis B virus, or hepatitis C virus infection, sarcoidosis or
any other immunodepressants in any of the patients. None of
the patients had evidence of malignant lymphoma at the
time of the study. The comparison of clinical and serological
characteristics between the patients included in this study
with SS and IgG4-DS is summarized in Table 2.
This study design was approved by the Ethics Committee
of Kyushu University, Japan, and written informed consent
was obtained from all of the patients and healthy controls
(IRB serial number: 25-287).2.2. Immunohistochemical analysis
For immunohistochemical analysis, 4-μm formalin-fixed,
paraffin-embedded sections were prepared and stained with
a conventional avidin–biotin complex technique as previously
described [13]. Anti-CD68 (catalog # ab955; Abcam, Cam-
bridge, MA, USA) and CD163 (catalog # NCL-CD163; Leica
Biosystems, Nussloch GmbH, Germany) mouse monoclonal
antibodies were used to analyze the protein expression of
CD68 and CD163, respectively. Anti-CCL18 (catalog #
ab104867; Abcam), IL-10 (catalog # ab34843; Abcam) and
IL-13 (catalog # HPA042421; Atlas Antibodies AB, Stockholm,
Sweden) rabbit polyclonal antibodies were used to analyze the
protein expression of CCL18, IL-10 and IL-13, respectively.
Tissue sections were sequentially incubated with primary
antibodies for 2.5 h then with biotinylated anti-mouse IgG and
anti-rabbit IgG secondary antibodies (Vector Laboratories,
Burlingame, CA, US), avidin–biotin–horseradish peroxidase
complex (Vector Laboratories), and 3,3′-diaminobenzidine
(Vector Laboratories). Mayer's hematoxylin was used for
counterstaining. Photomicrographs were obtained using a
light microscope equipped with a digital camera (BZ-9000
series; Keyence, Tokyo, Japan).2.3. RNA extraction and complementary DNA (cDNA)
synthesis
Total RNA was prepared from whole LSGs and SMGs by the
acidified guanidinium–phenol–chloroform method. One micro-
gram of total RNA was used for the synthesis of cDNA. Briefly,
RNA was incubated for 1 h at 42 °C with 20 U of RNase inhibitor
(Promega, Madison, WI, USA), 0.5 μg of oligo-1218 (Pharmacia,
Uppsala, Sweden), 0.5 mM of each deoxyribonucleotide tri-
phosphate (dNTP) (Pharmacia), 10 mM of dithiothreitol (DTT),
and 100 U of RNA reverse transcriptase (Life Technologies,
Gaithersburg, MD, USA).
2.4. Quantitative estimation of mRNA by real-time
PCR
The mRNA levels of the cytokines and chemokines were
analyzed quantitatively by real-time PCR using Light Cycler
Fast Start DNA Master mix SYBR Green III (Roche Diagnostics,
Mannheim, Germany) in a Light Cycler real-time PCR
instrument (version 3.5; Roche Diagnostics). The cytokines
and cell surface markers analyzed were CD68, CD163,
CCL18, IL-10, and IL-13. The primer sequences used were
as follows: β-actin (260 bp), forward 5′-GCA AAG ACC TGT
ACG CCA AC-3′, reverse 5′-CTA GAA GCA TTT GCG GTG
GA-3′; CD68 (199 bp), forward 5′-TCA GAA TGC ATC CCT TCG
AG-3′, reverse 5′-GAT GAG AGG CAG CAA GAT GG-3′; CD163
(168 bp), forward 5′-TGA TTT CGG ACT TCT CTC TGG-3′,
reverse 5′-ACT GGG CAG AGT GAA AGA TG-3′; CCL18
Figure 1 M1 and M2 macrophage localization in submandibular glands (SMGs). (A) mRNA expression levels of macrophage markers
(CD68, M1 and M2 macrophages; CD163, M2 macrophages) were examined in SMGs from controls (n = 10), patients with Sjögren's
syndrome (SS) (n = 10) and IgG4-related dacryoadenitis and sialoadenitis (IgG4-DS) (n = 7). Macrophage markers were quantitatively
estimated as described in the Materials and methods section. Significant differences between groups were determined by the
Mann–Whitney U test (*p b 0.05, **p b 0.01). (B) Distribution of M1 and M2 macrophages in SMGs from representative controls and
patients with chronic sialoadenitis [33], SS and IgG4-DS. Counterstaining was performed with Mayer's hematoxylin (blue). Higher
magnifications are displayed at the upper right. Scale bars, 100 μm. (C) Number and frequency of M2 macrophages per high-power
field (HPF) were counted in 4-mm2 sections from five different areas as described in the Materials and methods section. Statistically
significant differences between groups were determined by Mann–Whitney U tests (*p b 0.05, **p b 0.01).
12 S. Furukawa et al.(187 bp), forward 5′-AGC TCT GCT GCC TCG TCT AT-3′,
reverse 5′-CAG GCA TTC AGC TTC AGG TC-3′; IL-10 (144 bp),
forward 5′-TGA GAA CCA AGA CCC AGA CA-3′, reverse 5′-AAG
GCA TTC TTC ACC TGC TC-3′; and IL-13 (240 bp), forward
5′-GGT CAA CAT CAC CCA GAA CC-3′, reverse 5′-TTT ACA AAC
TGG GCC ACC TC-3′. The relative mRNA level was calculated
after normalizing to the housekeeping gene β-actin.2.5. Double immunofluorescence analysis
For double immunofluorescence analysis, 4-μmformalin-fixed,
paraffin-embedded sections were prepared and stained.
Sections were incubated with the primary antibody, CCL18
(Abcam), IL-10 (Abcam), or IL-13 (Atlas Antibodies AB) at room
temperature for 2 h after blocking with 1% BSA for 1 h, then
incubatedwith secondary antibody (1:100 dilution of Alexa 488USA) for 30 min. The sections were washed well, blocked with
1% BSA blocking buffer for 40 min, and incubated with the
primary antibodies, CD163 (clone EDHu-1; AbD Serotec,
Raleigh, NC, USA) at room temperature for 2 h. After
incubation, the sections were incubated with secondary
antibodies (1:100 dilution of Alexa 568) for 30 min at room
temperature. Slides were mounted (VectaMount, Vector
Laboratories) and kept in the dark. DAPI was used to stain
nuclei. Images were taken using a Keyence microscope
(BZ-9000 series), setting the background fluorescence level
with the negative controls.2.6. Evaluation of the severity of fibrosis
To evaluate fibrosis histologically, Masson's trichrome (MT)
staining (Polysciences, Warrington, PA, USA) was performed.
Figure 2 Localization of pro-fibrotic factors (CCL18, IL-10, and IL-13) in SMGs. (A) mRNA expression levels of pro-fibrotic factors in
SMGs from controls (n = 10), patients with SS (n = 10) and IgG4-DS (n = 7). Expression levels of pro-fibrotic factors were estimated
quantitatively as described in the Materials and methods section. Statistically significant differences between groups were
determined by Mann–Whitney U tests (*p b 0.05, **p b 0.01). (B) Distribution of fibrosis factors in SMGs from representative controls
and patients with CS, SS, and IgG4-DS. Counterstaining was performed with Mayer's hematoxylin (blue). Scale bars, 200 μm.
13M2 macrophages in IgG4-related dacryoadenitis and sialoadenitisIn short, 4-μm formalin-fixed, paraffin-embedded sections
were prepared and stained. Connective and fibrosis tissues
were selectively stained blue, whereas nuclei stained by
Weigert's iron hematoxylin were dark brown to black and the
cytoplasm was stained red. The fibrosis scores in SMGs were
defined as the ratio of the fibrotic area (blue) to the whole
stained area in a 4-mm2 field of view, from five different
areas.2.7. Statistical analysis
The statistical significance of the differences between the
groups was determined by the Mann–Whitney U test orSpearman's rank correlation as appropriate. All statistical
analyses in this study were performed using JMP software,
version 8 (SAS Institute, Cary, NC, USA). A p-value b0.05 was
considered statistically significant.3. Results
3.1. Expression of macrophage markers in SMGs
The mRNA levels of CD68 and CD163 in SMGs from SS and
IgG4-DS patients were significantly higher than those in
controls. Furthermore, the mRNA levels of CD68 and CD163
in IgG4-DS patients were significantly higher than those in SS
Figure 3 M2 macrophages produce pro-fibrotic factors in SMG in patients with IgG4-DS. Double immunofluorescence staining
performed with CD163 (red), pro-fibrotic factors (CCL18, IL-10, and IL-13) [23], and DAPI for staining nuclei (blue) as described in the
Materials and methods section. The images for CD163 and pro-fibrotic factors were merged (yellow). Scale bars, 50 μm.
14 S. Furukawa et al.patients (Fig. 1A). As specimens from CS patients were
formalin-fixed and paraffin-embedded tissues, the mRNA
levels in CS patients were not measured. The specimens
were also examined after the immunohistochemical staining
to evaluate the distribution of macrophages in SMGs.
Expression of CD68 was weakly detected in/around areas of
fibrosis or connective tissue in SMGs from controls, while it
was strongly detected in/around areas of fibrosis in SS, CS
and IgG4-DS patients. Expression of CD163 was not detected
in controls, but was weakly detected in/around fibrotic
lesions in SS and CS patients. Interestingly, expression of
CD163 was strongly detected in/around areas of fibrosis in
IgG4-DS patients (Fig. 1B). Moreover, the number of
CD163-positive cells and the CD163/CD68 ratio in SMGs
from IgG4-DS patients were significantly greater than those
in the other groups (Fig. 1C).3.2. Expression of pro-fibrotic factors in SMGs
As IL-10, IL-13, and CCL18 produced bymacrophages promote
fibrosis, we next compared the expression and distribution of
these pro-fibrotic factors between controls and patients. The
mRNA levels of CCL18, IL-10, and IL-13 in SMGs from SS and
IgG4-DS patients were significantly greater than those in
controls. Furthermore, the mRNA levels of CCL18, IL-10 and
IL-13 in IgG4-DS patients were significantly higher than those
in SS patients (Fig. 2A). Expression of CCL18, IL-10, and IL-13
could not be detected by immunohistochemistry in SMGs from
controls or CS patients, but could be detected in/around
ductal epithelial cells in SS patients. In contrast, expression
of CCL18, IL-10, and IL-13 was strongly detected in/around
areas of fibrosis in IgG4-DS patients (Fig. 2B).3.3. Co-localization of M2 macrophage markers and
pro-fibrotic factors in SMGs from IgG4-DS patients
To clarify whether M2 macrophages expressed the pro-fibrotic
factors, double immunofluorescence staining with CD163 and
CCL18, IL-10 or IL-13 was performed. As shown in Fig. 3,
CD163-positive cells (red) were co-localized with CCL18 and
IL-10 positive cells, while they only partly co-localized with
IL-13-positive cells. Therefore, M2 macrophages might pro-
mote fibrosis in SMGs from IgG4-DS patients through increased
production of IL-10 and CCL18.
3.4. Evaluation of fibrosis score in SMGs
Specimens were stained by MT staining to evaluate the
degree of fibrosis in SMGs. IgG4-DS patients showed severe
cordlike fibrosis with extensive eGC formation, while the
other groups showed only mild or moderate periductal
fibrosis (Fig. 4A). The fibrosis score of IgG4-DS was signif-
icantly higher than those in the other groups (Fig. 4B).
Furthermore, the fibrosis score was positively correlated
with the CD163/CD68 ratio in SMGs from IgG4-DS patients
but not in those from the other groups (Fig. 4C).
3.5. Expression of macrophage markers in other
organs from IgG4-DS patients
To confirm the changes in macrophage distribution in
IgG4-RD patients, specimens from other involved organs
including the lacrimal gland, pancreas, prostate gland, and
pleura from IgG4-DS patients included in this study were
examined by immunohistochemical staining. Expression of
Figure 4 Correlation between M2macrophages and fibrosis in SMGs. (A) Sections were stained byMasson's trichrome (MT) staining from
controls, patients with CS, SS, and IgG4-DS. MT staining stained nuclei (purple), cytoplasm (red) and collagen (connective tissue or
fibrosis) (blue) as described in the Materials and methods section. Lower magnifications are displayed in the upper line, and the higher
magnifications are displayed in the lower line. Scale bars, 200 μm (lower power field) and 50 mm (high power field). (B) Evaluation of
fibrosis score in the SMGs from controls (n = 10), patients with CS (n = 10), SS (n = 10), and IgG4-DS (n = 7). The fibrosis score was
calculated from MT staining as described in the Materials and methods section. Statistically significant differences between groups were
determined by one-way ANOVA (*p b 0.05, **p b 0.01). (C) Correlation between frequencies of M2 macrophage and fibrosis score.
Statistical significance of differences between groups was determined by Spearman's rank correlation (p b 0.05).
15M2 macrophages in IgG4-related dacryoadenitis and sialoadenitisCD68 and CD163 in these organs was strongly detected in/
around areas of fibrosis with results similar to those obtained
from SMGs (Fig. 5).4. Discussion
IgG4-RD is now recognized as a systemic disorder, character-
ized by high serum IgG4, marked infiltration of IgG4-positive
plasma cells and severe fibrosis with hyperplastic eGCs in
swollen lesions [11]. Although our previous data revealed that
Th2 adaptive immune responses induced IgG4 production and
eGC formation in IgG4-RD [13,14], themechanism of fibrosis inlesions remains to be fully elucidated. Recent studies have
reported that macrophages might play a critical role in IgG4
production in IgG4-RD [15,24]. As outlined above, macro-
phages can be classified as M1 and M2 macrophages based on
their response to the extracellular environment [25]. Notably,
M2 macrophages are activated by Th2 cytokines and promote
fibrosis by the production of pro-fibrotic factors (CCL18, IL-10
and IL-13) [26]. We therefore examined the M1 and M2
macrophage subsets in SMGs from SS, CS, and IgG4-DS
patients. Immunohistochemical staining indicated that ex-
pression of CD163 (M2 macrophage marker) was strongly
detected in IgG4-DS patients, whereas it was rarely detected
in controls, CS and SS patients. These findings were mirrored
Figure 5 Distribution of M1 and M2 macrophages in the other involved organs from patients with IgG4-DS including the lacrimal
gland, pancreas, prostate gland, and pleura. Counterstaining was performed with Mayer's hematoxylin (blue). The higher
magnifications are displayed at the upper right. Scale bars, 100 μm.
16 S. Furukawa et al.in other lesions including the lacrimal gland, pancreas,
pleura, and prostate gland from IgG4-RD patients. Interest-
ingly, the cell number and frequency of M2 macrophage in
IgG4-DS were significantly higher than those in the other
groups. To reveal the relationship between M2 macrophages
and fibrosis in SMGs from IgG4-DS patients, we also analyzed
the expression of pro-fibrotic factors such as CCL18, IL-10,
and IL-13. The expression patterns of CCL18 and IL-10 in
SMGs were similar to those of M2 macrophages in patients
with IgG4-DS. In contrast, IL-13 was mainly expressed on
other cells such as Th2 and mast cells in patients with
IgG4-DS. In this study the mRNA expression levels of CD163
and pro-fibrotic factors (CCL18, IL-10, and IL-13) in SMGs
from patients with IgG4-DS were higher than those in the
other groups. Furthermore, the fibrosis scores were posi-
tively correlated with the frequency of M2 macrophages onlyin patients with IgG4-DS. These results suggest that prefer-
ential M2 macrophages might be involved in fibrosis of
swollen lesions from IgG4-RD patients through the produc-
tion of CCL18 and IL-10. On the other hands, Th2 and mast
cells might promote fibrosis through the production of IL-13
without involving M2 macrophages.
IL-10 is well known as an immunosuppressive cytokine,
produced mostly by macrophages, Th2 cells, regulatory T
cells (Tregs) and dendritic cells (DCs), and is essential for the
maintenance of immunological self-tolerance and immune
homeostasis. Several studies have reported that IL-4 and
IL-10 are overexpressed locally in the lesions of IgG4-RD
patients and contribute to IgG4-specific class switching
[13,27,28]. With regard to fibrosis, IL-10 was identified as
an endogenous inhibitor of tissue fibrosis [29,30], while
recent studies demonstrated that IL-10 produced by M2
17M2 macrophages in IgG4-related dacryoadenitis and sialoadenitismacrophage had an important role in the renal and lung
fibrosis [31,32]. In this study, the localization of IL-10 in
SMGs from IgG4-DS patients was consistent with that of
production by M2 macrophages, suggesting that the majority
of IL-10 producing cells might be M2 macrophages and
deeply involved in fibrosis. In contrast, other IL-10 producing
cells such as Treg and plasmacytoid DC were also infiltrated
in salivary glands from IgG4-DS patients. However, these
cells were detected in/around GCs rather than around
fibrotic lesions, and might promote plasma cells to IgG4
production (manuscript in preparation).
CCL18 is one of the most highly expressed chemokines in
chronic inflammatory diseases including idiopathic pulmonary
fibrosis [33], bronchial asthma [34] and atopic dermatitis [35]. In
addition, CCL18 is now recognized as a chemokine with not only
fibrotic activity but also selective chemotactic activity on
peripheral blood T lymphocytes, especially Th2 cells [36,37].
Although IgG4-RD is considered a Th2-dominant disease [12], the
mechanism of Th2 polarization has yet to be elucidated.
Considering the current results, M2 macrophages might also
contribute to Th2 polarization of IgG4-RD by CCL18 production.
However, additional research is required to further elucidate the
involvement of innate immunity in the pathogenesis of IgG4-RD.
Fibrosis associated with a part of IgG4-RD including AIP,
IgG4-SC and IgG4-TIN has a characteristic irregular whorled
pattern, termed “storiform fibrosis” [19]. In this study, we
have confirmed that the production of IL-10 and CCL18 by
preferential M2 macrophages is associated with severe
fibrosis in IgG4-RD. However, the relationship between M2
macrophage and this fibrotic pattern in salivary glands was
not distinctive change, and requires more consideration for
other organs. Recent studies reported that rituximab
targeting peripheral CD20-positive plasma cells appeared
to be an effective treatment strategy for IgG4-RD [38,39]. In
addition, circulating plasmablasts, derived from the B cell
lineage, are also elevated in IgG4-RD patients, especially
with resistance to rituximab [40,41]. This is attributed to
the fact that plasmablasts lack surface expression of CD20
and demonstrate a resistance to direct depletion by
rituximab. Therefore, IgG4-positive plasmablasts are con-
sidered to be prominently involved in the pathogenesis of
IgG4-RD. Interestingly, after interacting with antigens
exposed on macrophages, marginal zone B cells rapidly
differentiate into plasmablasts [42]. These results suggest
that macrophages might play an effective role in plasma-
blast activation of IgG4-RD. A more thorough understanding
of the immune mechanism of IgG4-RD, especially the role of
innate immune cells, could lead to the development of
novel pharmacological strategies aimed at disrupting the
recruitment of inflammatory cells to the local lesion and
inhibiting the initiation of IgG4-RD.Conflict of interest
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